3D printed spherical mini-tablets: Geometry versus composition effects in controlling dissolution from personalised solid dosage forms
نویسندگان
چکیده
Oral dosage forms are by far the most common prescription and over-the-counter pharmaceutical used worldwide. However, many patients suffer from adverse effects caused their use of “one-size fits all” mass produced commercially available solid forms, whereby they do not receive dedicated medication or adjusted to specific needs. The development 3D printing paves way for personalised medicine. This work focuses on therapies hypertensive using nifedipine as model drug. printed full channelled spherical mini-tablets with enhanced surface area (1.6-fold higher) were modified PVA commercial filaments loaded passive diffusion (PD), Kollidon VA64 (KVA) ethylcellulose (EC) based prepared hot-melt extrusion (HME). Drug loading ranged 3.7% 60% employed technique, a 13-fold higher drug achieved HME compared PD. Composition was found have more significant impact dissolution than geometry area. Both KVA EC-based formulations exhibited biphasic zero-order drug-release profile. Physicochemical characterization revealed that in amorphous form KVA-based end-products which led greater control over 24 h period low levels crystallinity PXRD. proposed provide versatile technology high control, easily adaptable patient disease
منابع مشابه
"In vitro" dissolution tests for solid oral dosage forms.
©2010 Particle Sciences, Inc. All rights reserved. the drug substance and involves two steps: dissolution and absorption (or permeability). Understanding the multi-step dissolution process is essential to proper in vitro method development. Dissolution is the process of extracting the API out of the dosage form solid-state matrix into solution within the gastrointestinal tract. Absorption is th...
متن کاملStudy of Ofloxacin Enantiomers Dissolution from Selected Solid Dosage Forms Using High Performance Capillary Electrophoresis Method.
The commercially available coated tablets containing either racemic form of ofloxacin (Tarivid 200 mg, OfloHexal 200 mg and Ofloxacin-Ratiopharm 200 mg) or only levofloxacin S-(-)-isomer (Tavanic 250 mg) were examined. The aim of our study was to establish the kinetics of dissolution rate process of ofloxacin optical isomers (S-(-) and R-(+)-ofloxacin) from solid oral dosage forms using flow-th...
متن کاملDissolution Profile of Mefenamic Acid Solid Dosage Forms in Two Compendial and Biorelevant (FaSSIF) Media.
Mefenamic acid is a non-steroidal anti-inflammatory drug (NSAID) that is widely used for the treatment of mild-to-moderate pain. Mefenamic acid belongs to the Biopharmaceutical Classification System (BCS) class II drug which has lower water solubility but high permeability. There are two different compendial methods available for dissolution tests of mefenamic acid solid dosage forms, i.e. meth...
متن کاملDissolution enhancement and formulation of rapid-release lornoxicam mini-tablets.
The aim was to enhance the dissolution of lornoxicam (LOR) and to produce mini-tablets with an optimised system to provide a rapid-release multi-particulate formulation. LOR systems were prepared through co-evaporation with either polyethylene glycol 6000 or Pluronic(®) F-68 (PLU) and adsorption onto Neusilin(®) US2 alone or co-adsorption in the presence of different amounts of polysorbate 80. ...
متن کاملLubricants in Pharmaceutical Solid Dosage Forms
Lubrication plays a key role in successful manufacturing of pharmaceutical solid dosage forms; lubricants are essential ingredients in robust formulations to achieve this. Although many failures in pharmaceutical manufacturing operations are caused by issues related to lubrication, in general, lubricants do not gain adequate attention in the development of pharmaceutical formulations. In this p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Pharmaceutics
سال: 2021
ISSN: ['0378-5173', '1873-3476']
DOI: https://doi.org/10.1016/j.ijpharm.2021.120336